BioNexus Enters $500M Equity Purchase Agreement with ARC Group International

BioNexus Gene Lab entered into a $500,000,000 Equity Purchase Agreement with ARC Group International.The Company believes this facility will provide it with long-term, discretionary access to capital to advance its strategic initiatives, including the commercialization of the VitaGuard minimal residual disease platform, the addition of contract development and manufacturing organization services to its business regionally, and building the Company's therapeutic development and commercialization programs. Under the terms of the Agreement, BGLC, at its sole discretion, may issue and sell registered shares of its common stock to ARC over the commitment period of 36 months. In consideration for ARC's commitment, BGLC issued 175,000 shares of common stock as a one-time fee, priced at the closing price on Nov 26, 2025 - $4.32. ARC is prohibited from owning more than 9.99% of BGLC's outstanding shares at any time and is restricted from short-selling or hedging the Company's securities. The Company will file a registration statement to register the resale of shares issued under the Facility, and no shares may be sold prior to registration. The Facility complements BGLC's previously announced $20M At-The-Market program, enhancing the Company's financial flexibility while preserving strategic control over the timing and scale of capital deployment.